Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.020
-0.010 (-0.97%)
At close: May 11, 2026, 4:00 PM EDT
1.040
+0.020 (1.96%)
After-hours: May 11, 2026, 7:46 PM EDT
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Lishan Aklog |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 917 813 1828 |
| Website | luciddx.com |
Stock Details
| Ticker Symbol | LUCD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 1799011 |
| CUSIP Number | 54948X109 |
| ISIN Number | US54948X1090 |
| Employer ID | 82-5488042 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Michael Adam Gordon | General Counsel and Secretary |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Joseph Willis M.D. | Co-founder and Strategic Advisor |
| Dr. Amitabh Chak M.D. | Co-Founder and Strategic Advisor |
| Helen Moinova Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Brian J. deGuzman M.D. | Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Senior Vice President and Chief Scientific Officer |
| Matthew Riley | Director of Investor Relations |
| Dr. Deepika A. Lakhani Ph.D. | Senior Vice President, Chief Regulatory and Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2026 | 8-K | Current Report |
| Apr 23, 2026 | 424B5 | Filing |
| Apr 23, 2026 | 8-K | Current Report |
| Apr 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | EFFECT | Notice of Effectiveness |